+

WO2003033710A1 - Nouvelle n-acetylglucosamine transferase, acide nucleique codant cette enzyme, anticorps dirige contre cette enzyme et utilisation de l'enzyme pour diagnostiquer un cancer ou une tumeur - Google Patents

Nouvelle n-acetylglucosamine transferase, acide nucleique codant cette enzyme, anticorps dirige contre cette enzyme et utilisation de l'enzyme pour diagnostiquer un cancer ou une tumeur Download PDF

Info

Publication number
WO2003033710A1
WO2003033710A1 PCT/JP2002/010710 JP0210710W WO03033710A1 WO 2003033710 A1 WO2003033710 A1 WO 2003033710A1 JP 0210710 W JP0210710 W JP 0210710W WO 03033710 A1 WO03033710 A1 WO 03033710A1
Authority
WO
WIPO (PCT)
Prior art keywords
tumor
same
enzyme
cancer
nucleic acid
Prior art date
Application number
PCT/JP2002/010710
Other languages
English (en)
French (fr)
Inventor
Hisashi Narimatsu
Niro Inaba
Toshie Iwai
Original Assignee
National Institute Of Advanced Industrial Science And Technology
Japan Genome Solutions, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institute Of Advanced Industrial Science And Technology, Japan Genome Solutions, Inc. filed Critical National Institute Of Advanced Industrial Science And Technology
Priority to CA 2470711 priority Critical patent/CA2470711C/en
Priority to AT02777847T priority patent/ATE497536T1/de
Priority to JP2003536435A priority patent/JPWO2003033710A1/ja
Priority to DE60239103T priority patent/DE60239103D1/de
Priority to DK02777847T priority patent/DK1447448T3/da
Priority to US10/492,819 priority patent/US7323324B2/en
Priority to EP02777847A priority patent/EP1447448B1/en
Publication of WO2003033710A1 publication Critical patent/WO2003033710A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PCT/JP2002/010710 2001-10-16 2002-10-16 Nouvelle n-acetylglucosamine transferase, acide nucleique codant cette enzyme, anticorps dirige contre cette enzyme et utilisation de l'enzyme pour diagnostiquer un cancer ou une tumeur WO2003033710A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA 2470711 CA2470711C (en) 2001-10-16 2002-10-16 Novel n-acetylglucosamine transferase, nucleic acid encoding the same, antibody against the same and use thereof for diagnosing cancer or tumor
AT02777847T ATE497536T1 (de) 2001-10-16 2002-10-16 Neue n-acetylglucosamin transferase, codierende nukleinsäuren, spezifische antikörper, sowie verwendung zur krebsdiagnose
JP2003536435A JPWO2003033710A1 (ja) 2001-10-16 2002-10-16 新規ｎ−アセチルグルコサミン転移酵素、それをコードする核酸及びそれに対する抗体並びにこれらの癌若しくは腫瘍診断用途
DE60239103T DE60239103D1 (de) 2001-10-16 2002-10-16 Neue n-acetylglucosamin transferase, codierende nukleinsäuren, spezifische antikörper, sowie verwendung zur krebsdiagnose
DK02777847T DK1447448T3 (da) 2001-10-16 2002-10-16 Ny N-acetylglucosamin-transferase, kodende nukleinsyre for den samme, antistof mod den samme og anvendelser deraf til diagnosticering af cancer eller tumor
US10/492,819 US7323324B2 (en) 2001-10-16 2002-10-16 N-Acetylglucosamine transferase, nucleic acid encoding the same, antibody against the same and use thereof for diagnosing cancer or tumor
EP02777847A EP1447448B1 (en) 2001-10-16 2002-10-16 Novel n-acetylglucosamine transferase, nucleic acid encoding the same, antibody against the same and use thereof for diagnosing cancer or tumor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-318676 2001-10-16
JP2001318676 2001-10-16

Publications (1)

Publication Number Publication Date
WO2003033710A1 true WO2003033710A1 (fr) 2003-04-24

Family

ID=19136339

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/010710 WO2003033710A1 (fr) 2001-10-16 2002-10-16 Nouvelle n-acetylglucosamine transferase, acide nucleique codant cette enzyme, anticorps dirige contre cette enzyme et utilisation de l'enzyme pour diagnostiquer un cancer ou une tumeur

Country Status (8)

Country Link
US (1) US7323324B2 (ja)
EP (1) EP1447448B1 (ja)
JP (1) JPWO2003033710A1 (ja)
AT (1) ATE497536T1 (ja)
CA (1) CA2470711C (ja)
DE (1) DE60239103D1 (ja)
DK (1) DK1447448T3 (ja)
WO (1) WO2003033710A1 (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006022027A (ja) * 2004-07-07 2006-01-26 National Institute Of Advanced Industrial & Technology β１，３−Ｎ−アセチルグルコサミン転移酵素を含む、細胞移動活性および／または細胞分化を調節する医薬組成物
WO2006064591A1 (ja) * 2004-12-13 2006-06-22 National University Corporation Okayama University 基板、及び標的物質の定量方法
JP2009018999A (ja) * 2007-07-10 2009-01-29 National Institute Of Advanced Industrial & Technology 抗癌剤抵抗性の抑制剤

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005065687A (ja) * 2003-01-23 2005-03-17 National Institute Of Advanced Industrial & Technology β１，３−Ｎ−アセチル−Ｄ−ガラクトサミン転移酵素タンパク質及びそれをコードする核酸、並びにそれを用いた癌化検定方法
KR20230161535A (ko) 2016-07-26 2023-11-27 바이오마린 파머수티컬 인크. 신규 아데노-관련 바이러스 캡시드 단백질
MX2020011937A (es) 2018-05-09 2021-01-29 Biomarin Pharm Inc Metodos de tratamiento de fenilcetonuria.
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
KR20220098210A (ko) 2019-11-14 2022-07-11 바이오마린 파머수티컬 인크. 간-특이적 유전자 요법 벡터를 이용한 유전성 혈관 부종의 치료
WO2021183895A1 (en) 2020-03-13 2021-09-16 Biomarin Pharmaceutical Inc. Treatment of fabry disease with aav gene therapy vectors
AR122409A1 (es) 2020-04-03 2022-09-07 Biomarin Pharm Inc Tratamiento de la fenilcetonuria con aav y formulaciones terapéuticas
EP4408481A2 (en) 2021-10-01 2024-08-07 BioMarin Pharmaceutical Inc. Treatment of hereditary angioedema with aav gene therapy vectors and therapeutic formulations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000848A1 (fr) * 1999-06-29 2001-01-04 Kyowa Hakko Kogyo Co., Ltd. Polypeptide utile

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2438215A1 (en) * 2001-02-09 2002-08-22 Incyte Genomics, Inc. Putative human enzymes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000848A1 (fr) * 1999-06-29 2001-01-04 Kyowa Hakko Kogyo Co., Ltd. Polypeptide utile

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BIERHUIZEN M.F. ET AL.: "Expression cloning of a cDNA encoding UDP-GlcNAc:Gal beta 1-3-GalNAc-R (GlcNAc to GalNAc) beta 1-6-glcNAc transferase by gene transfer into CHO cells expressing polyoma large tumor antigen", PROC. NATL. ACAD. SCI. USA, vol. 89, no. 19, 1 October 1992 (1992-10-01), pages 9326 - 9330, XP002961059 *
BROCKHAUSEN I. ET AL.: "Mucin synthesis. UDP-GlcNAc:GalNAc-R beta 3-N-acetylglucosaminyltransferase and UDP-GlcNAc:GlcNAc beta 1-3GalNAc-R (GlcNAc to GalNAc) beta 6-N-acetylglucosaminyltransferase from pig and rat colon mucosa", BIOCHEMISTRY, vol. 24, no. 8, 9 April 1985 (1985-04-09), pages 1866 - 1874, XP002961057 *
DATABASE PUBMED [online] VAVASSEUR F. ET AL.: "Synthesis of O-glycan core 3: characterization of UDP-GlcNAc: GalNAc-R beta 3-N-acetyl-glucosaminyltransferase activity from colonic mucosal tissues and lack of the activity in human cancer cell lines", XP002961056, accession no. NCBI Database accession no. 7655172 *
GLYCOBIOLOGY, vol. 5, no. 3, May 1995 (1995-05-01), pages 351 - 357 *
IWAI T. ET AL.: "Molecular cloning and characterization of a novel UDP-GlcNAc:GalNAc-peptide beta1,3-N-acetylglucosaminyltransferase (beta3Gn-T6), an enzyme synthesizing the core 3 structure of O-glycans", J. BIOL. CHEM., vol. 277, no. 15, 12 April 2002 (2002-04-12), pages 12802 - 12809, XP002961055 *
SASAKI K. ET AL.: "Expression cloning of cDNA encoding a human beta-1,3-N-acetylglucosaminyltransferase that is essential for poly-N-acetyllactosamine synthesis", PROC. NATL. ACAD. SCI. USA, vol. 94, no. 26, 23 December 1997 (1997-12-23), pages 14294 - 14299, XP002959550 *
SHIRAISHI N. ET AL.: "Identification and characterization of three novel beta 1,3-N-acetylglucosaminyltransferases structurally related to the beta 1,3-galactosyltransferase family", J. BIOL. CHEM., vol. 276, no. 5, 2 February 2001 (2001-02-02), pages 3498 - 3507, XP002961826 *
TOGAYACHI A. ET AL.: "Molecular cloning and characterization of UDP-GlcNAc:lactosylceramide beta 1,3-acetylglucosaminyltransferase (beta 3Gn-T5), an essential enzyme for the expression of HNK-1 and Lewis X epitopes on glycolipids", J. BIOL. CHEM., vol. 276, no. 25, 22 June 2001 (2001-06-22), pages 22032 - 22040, XP002906784 *
ZHOU D. ET AL.: "A beta-1,3-N-acetylglucosaminyltransferase with poly-N-acetyllactosamine synthase activity is structurally related to beta-1,3-galactosyltransferases", PROC. NATL. ACAD. SCI. USA, vol. 96, no. 2, 19 January 1999 (1999-01-19), pages 406 - 411, XP002928041 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006022027A (ja) * 2004-07-07 2006-01-26 National Institute Of Advanced Industrial & Technology β１，３−Ｎ−アセチルグルコサミン転移酵素を含む、細胞移動活性および／または細胞分化を調節する医薬組成物
JP4565177B2 (ja) * 2004-07-07 2010-10-20 独立行政法人産業技術総合研究所 β１，３−Ｎ−アセチルグルコサミン転移酵素を含む、細胞移動活性および／または細胞分化を調節する医薬組成物
WO2006064591A1 (ja) * 2004-12-13 2006-06-22 National University Corporation Okayama University 基板、及び標的物質の定量方法
JPWO2006064591A1 (ja) * 2004-12-13 2008-06-12 国立大学法人 岡山大学 基板、及び標的物質の定量方法
JP4882071B2 (ja) * 2004-12-13 2012-02-22 国立大学法人 岡山大学 基板、及び標的物質の定量方法
JP2009018999A (ja) * 2007-07-10 2009-01-29 National Institute Of Advanced Industrial & Technology 抗癌剤抵抗性の抑制剤

Also Published As

Publication number Publication date
CA2470711C (en) 2011-07-12
US20060234220A1 (en) 2006-10-19
JPWO2003033710A1 (ja) 2005-02-03
DK1447448T3 (da) 2011-05-02
DE60239103D1 (de) 2011-03-17
CA2470711A1 (en) 2003-04-24
EP1447448B1 (en) 2011-02-02
ATE497536T1 (de) 2011-02-15
US7323324B2 (en) 2008-01-29
EP1447448A1 (en) 2004-08-18
EP1447448A4 (en) 2004-12-22

Similar Documents

Publication Publication Date Title
WO2004016733A3 (en) Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
WO2003022995A3 (en) Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
AU3246300A (en) Polypeptides having galactose oxidase activity and nucleic acids encoding same
DE69840387D1 (de) Nik proteine, nukleinsäure sowie verfahren
WO2003033710A1 (fr) Nouvelle n-acetylglucosamine transferase, acide nucleique codant cette enzyme, anticorps dirige contre cette enzyme et utilisation de l'enzyme pour diagnostiquer un cancer ou une tumeur
WO1998037181A3 (en) Telomerase catalytic subunit gene and encoded protein
EP1734134A3 (en) A novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer
CY1113064T1 (el) Νουκλεϊνικο οξυ και αντιστοιχη πρωτεϊνη με τιτλο 184ρ1ε2 χρησιμα στη θεραπεια και ανιχνευση καρκινου
WO2004098515A3 (en) Nucleic acids and corresponding proteins entitled 109p1d4 useful in treatment and detection of cancer
WO2000052136A3 (en) Human glycosylation enzymes
AU5579096A (en) Diagnostic methods and gene therapy using reagents derived from the human metastasis suppressor gene KAI1
WO2002072785A3 (en) Nucleic acid and corresponding protein entitled 125p5c8 useful in treatment and detection of cancer
CN106854244A (zh) 一种针对her3的纳米抗体及其临床应用
WO2002060953A3 (en) Nucleic acid and encoded zinc transporter protein entitled 108p5h8 useful in treatment and detection of cancer
CA2374156A1 (en) Microbial polynucleotides expressed during infection of a host
EP1757684A3 (en) A 2,6-beta-D-fructan hydrolase enzyme and processes for using the enzyme
WO2002083928A3 (en) Nucleid acid and corresponding protein entitled 158p3d2 useful in treatment and detection of cancer
WO2006055004A8 (en) Nucleic acids and corresponding proteins entitled 158p3d2 useful in treatment and detection of cancer
WO2002092842A3 (en) Nucleic acids and corresponsing proteins entitled 101p3a11 or phor-1 useful in treatment and detection of cancer
WO2002086067A3 (en) Mycobacterial sulfation pathway proteins and methods of use thereof
WO1998051782A3 (en) Human 3-hydroxyisobutyryl-coenzyme a hydrolase
EP1576096A4 (en) N-ACETYLGLUCOSAMINYLTRANSFERASE VB CODING SEQUENCE, RECOMBINANT CELLS AND METHOD
WO2002018584A3 (en) Xage-1, a gene expressed in multiple cancers, and uses thereof
WO2005049818A3 (en) Genes encoding human deubiquitinating enzymes
CN106854246A (zh) 一种针对pi3k的纳米抗体及其临床应用

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003536435

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002777847

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2470711

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2002777847

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006234220

Country of ref document: US

Ref document number: 10492819

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10492819

Country of ref document: US

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载